Some more: Does anyone know what a "KOL" is? Sounds

New Post Public Reply Private Reply Replies (1) Message Board
Bravo16
319
Some more: Does anyone know what a "KOL" is?

Sounds like a spokesperson of sorts and the way Joe describes it here is that the ones he uses are doing it essentially for free because they know how good GNBT's the science

Joseph Moscato

only people to me are KOLS I listen to, academia is never something a drug developer like myself or my peers would ever take seriously, listen to, and even consider, and that’s just the way it is, if it’s cancer I want to know all the drugs you’ve been part of developing, does not matter if they have been commercialized or not, what matters is that clinician being on the front line and have participated because of their knowledge in all drug trials, why, they have the knowledge in the pathway, they have the experience and know what works and what doesn’t in regard to mechanism of action without them you got nothing, a KOL also gets paid an honorarium of about 1,500.00 a year and his expenses paid to go to conferences and talk you up and represent the science, if you have the best of the best on your team for this you know they believe in your science and they want to be part of the next big thing, then there is those same kols if the get paid big money or consideration that tells you something else, it means they are not sure about your science and want to be compensated for their time because it won’t probably be the next big thing, then their are the experts or supposed experts with big names that aren’t in let’s say breast cancer but the biggest in another area, or their a surgeon, big red flag that means they make a lot and your science is garbage, in addition as it pertains the the best surgeons on the planet you see one of them in science for sure they are getting paid big, huge red flag, why would a drug developer have a surgeon on board, cause they don’t know the business, that’s never taken seriously in fact it’s a joke, surgeons cut things out, they do not treat so why are they in drug development, because of the almighty dollar and lack of knowledge of the companies management team, the goal is always to partner with big pharma when the time is right and these signals will get your thrown out an office rather then sit down let’s discuss your science, so no I do not take any kind of Dr’s word or hyperbole who is not a KOL in the field you are developing that drug in, I just normally laugh!

Jay Colavita

I'm impressed with the explanation about the distinction of whether the opinion is actually factual or monetary driven. Everyone has an opinion and some are assholes and stink! I know you and you demand exceptional accomplishments only surrounding yourself with the best. I have faith under your direction your team will provide the best long term solution to this dilemma.

Joseph Moscato yes and we do have the best in my humble opinion

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 43

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 87

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 12

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 34

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 55

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 31

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Join the Challenge: Investors Pursue Justice Against TLX

Updated Category News Views 164

Opportunity for Investors in Telix Pharmaceuticals Ltd. Attention, investors! A significant event has unfolded for those who have purchased securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). The Rosen Law Firm, well-known for representing investors' rights, has initiated a class action lawsuit on behalf of these investors. This development presents a chance for you...

Continue Reading
Turvo and SMC3 Forge Alliance to Enhance Freight Efficiency

Updated Category News Views 158

Strategic Partnership Between Turvo and SMC3 Industry leaders are joining forces to enhance freight management solutions, facilitated by insights from a global logistics company. Turvo, known for its collaborative application tailored for the supply chain, has announced an integration partnership with SMC3, a respected provider of less-than-truckload (LTL) freight...

Continue Reading
Fnac Darty Takes Major Steps in Unieuro Acquisition Process

Updated Category News Views 148

Fnac Darty Makes Progress in Unieuro Acquisition Fnac Darty has recently announced significant developments regarding its acquisition of Unieuro. The authorization to officially notify this transaction was granted by the European Commission, following a pre-notification phase that lasted several months. This is an exciting development for shareholders and has set the...

Continue Reading
LOGISTEC Appoints Cleidy Liborio Fernandes as CCO for Growth

Updated Category News Views 202

CLEIDY LIBORIO FERNANDES JOINS LOGISTEC AS CHIEF COMMERCIAL OFFICER LOGISTEC, a prominent provider of marine and environmental services in North America, is delighted to announce the appointment of Cleidy Liborio Fernandes as the new Chief Commercial Officer. Cleidy's extensive background in international business and strategic development is expected to spearhead the...

Continue Reading
IMUNON Inc's Latest Developments Drive Stock Surge Today

Updated Category News Views 233

IMUNON Inc's Stock Surge Explained Shares of IMUNON Inc (NASDAQ: IMNN) are seeing a remarkable uptick in trading this Wednesday. The excitement is largely due to the company achieving a significant clinical milestone for its lead drug candidate, IMNN-001. This news has generated substantial interest among investors and highlights IMUNON's progress in the pharmaceutical...

Continue Reading